Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Quince Therapeutics ( (QNCX) ) has provided an update.
On March 16, 2026, Quince Therapeutics received notice from Nasdaq that its common stock had traded below the $1.00 minimum bid price for 30 consecutive business days, triggering a 180-day grace period to regain compliance by maintaining a closing bid of at least $1.00 for at least ten consecutive sessions. Failure to do so by the September 14, 2026 deadline could lead to a transfer to the Nasdaq Capital Market, potential reverse split considerations, or, if unresolved, delisting proceedings subject to appeal.
On March 17, 2026, Nasdaq separately notified Quince that its market value of listed securities had fallen below the $50 million threshold for 30 straight business days, also giving the company until September 14, 2026 to restore its MVLS to at least that level for a minimum of ten consecutive trading days. While the stock continues to trade without interruption on the Nasdaq Global Select Market, the dual deficiency notices highlight mounting listing-compliance pressure for Quince and underscore the risk of a market downgrade or eventual delisting if it cannot improve its share price and market value.
The most recent analyst rating on (QNCX) stock is a Sell with a $0.26 price target. To see the full list of analyst forecasts on Quince Therapeutics stock, see the QNCX Stock Forecast page.
Spark’s Take on QNCX Stock
According to Spark, TipRanks’ AI Analyst, QNCX is a Underperform.
The score is driven primarily by very weak financial performance (no revenue, large losses, sustained cash burn, and a significantly weakened equity position with higher leverage). Technicals also weigh on the score due to a strong downtrend, while valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on QNCX stock, click here.
More about Quince Therapeutics
Quince Therapeutics, Inc. operates in the biopharmaceutical sector, though the latest notice from Nasdaq focuses solely on its stock listing status rather than its specific drug portfolio or therapeutic focus. The company’s shares trade on the Nasdaq Global Select Market under the ticker symbol QNCX, where it must comply with Nasdaq’s quantitative listing standards for bid price and market value of listed securities.
Average Trading Volume: 65,468,404
Technical Sentiment Signal: Sell
Current Market Cap: $4.88M
For detailed information about QNCX stock, go to TipRanks’ Stock Analysis page.